Phase 3 Recruiting Academic/Other
This Phase III Trial will determine whether adjuvant chemotherapy (ACT) added to ovarian function suppression (OFS) plus endocrine therapy (ET) is superior to OFS plus ET in improving invasive breast cancer-free survival (IBCFS) among prem…
Sponsor: NRG Oncology
NCT ID: NCT05879926
Sites in Arkansas: - Mercy Hospital Fort Smith — Fort Smith, Arkansas
- NEA Baptist Memorial Hospital and Fowler Family Cancer Center - Jonesboro — Jonesboro, Arkansas
- Baptist Health Medical Center - Little Rock — Little Rock, Arkansas
- CARTI Cancer Center — Little Rock, Arkansas
- University of Arkansas for Medical Sciences — Little Rock, Arkansas
Phase 3 Recruiting Academic/Other
This phase III trial compares the effect of olaparib for one year versus two years, with or without bevacizumab, for the treatment of BRCA 1/2 mutated or homologous recombination deficient stage III or IV ovarian cancer. Olaparib is a poly…
Sponsor: NRG Oncology
NCT ID: NCT06580314
Sites in Arkansas: - Highlands Oncology Group - Fayetteville — Fayetteville, Arkansas
- Mercy Hospital Fort Smith — Fort Smith, Arkansas
- CARTI Cancer Center — Little Rock, Arkansas
- University of Arkansas for Medical Sciences — Little Rock, Arkansas
- Highlands Oncology Group - Rogers — Rogers, Arkansas
Phase 3 Recruiting Network
This phase III trial studies how well active surveillance help doctors to monitor subjects with low risk germ cell tumors for recurrence after their tumor is removed. When the germ cell tumor has spread outside of the organ in which it dev…
Sponsor: Children's Oncology Group
NCT ID: NCT03067181
Sites in Arkansas: - CHI Saint Vincent Cancer Center Hot Springs — Hot Springs, Arkansas
- Arkansas Children's Hospital — Little Rock, Arkansas
- CARTI Cancer Center — Little Rock, Arkansas
- University of Arkansas for Medical Sciences — Little Rock, Arkansas
Phase 3 Recruiting Network
This phase III trial compares the effect of giving triptorelin vs no triptorelin in preventing ovarian damage in adolescents and young adults (AYAs) with cancer receiving chemotherapy with an alkylating agents. Alkylating agents are part o…
Sponsor: Children's Oncology Group
NCT ID: NCT06513962
Sites in Arkansas: - Mercy Hospital Fort Smith — Fort Smith, Arkansas
- Arkansas Children's Hospital — Little Rock, Arkansas
- CARTI Cancer Center — Little Rock, Arkansas
Phase 3 Recruiting Industry
This study will assess the safety and efficacy of avutometinib (VS-6766) in combination with defactinib versus Investigator's choice of treatments (ICT) in subjects with recurrent LGSOC who have progressed on a prior platinum-based therapy.
Sponsor: Verastem, Inc.
NCT ID: NCT06072781
Sites in Arkansas: - University of Arkansas — Little Rock, Arkansas
Phase 2 Recruiting NIH
This ComboMATCH patient screening trial is the gateway to a coordinated set of clinical trials to study cancer treatment directed by genetic testing. Patients with solid tumors that have spread to nearby tissue or lymph nodes (locally adva…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05564377
Sites in Arkansas: - NEA Baptist Memorial Hospital and Fowler Family Cancer Center - Jonesboro — Jonesboro, Arkansas
Phase 1, Phase 2 Recruiting Industry
This clinical trial is evaluating a drug called ART0380 in participants with advanced or metastatic solid tumors. The main goals of this study are to: * Find the recommended dose of ART0380 that can be given safely to participants alone an…
Sponsor: Artios Pharma Ltd
NCT ID: NCT04657068
Sites in Arkansas: - University of Arkansas - Winthrop P. Rockefeller Cancer Institute — Little Rock, Arkansas
Phase 1, Phase 2 Recruiting Industry
The primary objectives of the study are: (1) in the dose-escalation part: to evaluate safety and tolerability and to determine the recommended Phase 2 dose (RP2D) of farletuzumab ecteribulin (MORAb-202) in participants with selected tumor …
Sponsor: Eisai Inc.
NCT ID: NCT04300556
Sites in Arkansas: - Universty of Arkansas for Medical Sciences — Little Rock, Arkansas
Phase 1 Recruiting Industry
This trial will look at a drug called sigvotatug vedotin (SGN-B6A) alone and with pembrolizumab, with or without chemotherapy, to find out whether it is safe for people who have solid tumors. It will study sigvotatug vedotin to find out wh…
Sponsor: Seagen, a wholly owned subsidiary of Pfizer
NCT ID: NCT04389632
Sites in Arkansas: - Highlands Oncology Group — Fayetteville, Arkansas
- Highlands Oncology Group — Rogers, Arkansas
- Highlands Oncology Group — Springdale, Arkansas
Phase 1 Recruiting Industry
The goal of the Dose Escalation phase of the study is to evaluate the safety, tolerability, pharmacokinetics (PK) and preliminary anti-tumor activity to determine the preliminary recommended dose for expansion (RDE) of NKT3964 in adults wi…
Sponsor: NiKang Therapeutics, Inc.
NCT ID: NCT06586957
Sites in Arkansas: - University of Arkansas Medical School — Little Rock, Arkansas
Phase 1 Recruiting Industry
This is a Phase 1a/1b, open-label, dose escalation and expansion study to evaluate the safety and efficacy of CTIM-76 (study drug), a CLDN6-directed T cell-engaging bispecific antibody , in participants with platinum-refractory/resistant o…
Sponsor: Context Therapeutics Inc.
NCT ID: NCT06515613
Sites in Arkansas: - University of Arkansas Winthrop P. Rockefeller Cancer Institute — Little Rock, Arkansas
Phase 1 Recruiting Industry
HWK-016-101 is a multicenter, open-label, first-in-human (FIH) Phase 1 study evaluating HWK-016, a targeted antibody-drug conjugate (ADC) in adult participants with advanced or metastatic solid tumors. The study employs a dose escalation a…
Sponsor: Whitehawk Therapeutics, Inc.
NCT ID: NCT07470853
Sites in Arkansas: - University of Arkansas - Winthrop P. Rockefeller Cancer Institute — Little Rock, Arkansas
Phase 1 Recruiting Industry
The primary objective of this trial is to evaluate ovarian suppression following treatment with ZOLADEX 10.8 mg by luteinizing hormone (LH).
Sponsor: TerSera Therapeutics LLC
NCT ID: NCT07310420
Sites in Arkansas: - Genesis Cancer and Blood Institute — Hot Springs, Arkansas
Phase 1 Recruiting Industry
This is a first-in-human, open-label, dose-escalation, dose-optimization trial designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and antitumor activity of MEN2501 monotherapy in adult participants with plat…
Sponsor: Stemline Therapeutics, Inc.
NCT ID: NCT07226427
Sites in Arkansas: - Highlands Oncology Group — Springdale, Arkansas
Recruiting Academic/Other
This study collects blood and tissue samples from patients with cancer and without cancer to evaluate tests for early cancer detection. Collecting and storing samples of blood and tissue from patients with and without cancer to study in th…
Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT05334069
Sites in Arkansas: - Mercy Hospital Fort Smith — Fort Smith, Arkansas
- CARTI Cancer Center — Little Rock, Arkansas
NA Recruiting Academic/Other
This clinical trial evaluates how well two surgical procedures (bilateral salpingectomy and bilateral salpingo-oophorectomy) work in reducing the risk of ovarian cancer for individuals with BRCA1 mutations. Bilateral salpingectomy involves…
Sponsor: NRG Oncology
NCT ID: NCT04251052
Sites in Arkansas: - University of Arkansas for Medical Sciences — Little Rock, Arkansas
Recruiting Industry
International registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool, powered by a virtual tumor boards (VTB) program, and its clinic…
Sponsor: Massive Bio, Inc.
NCT ID: NCT03452774
Sites in Arkansas: - Massive Bio SYNERGY-AI site — Little Rock, Arkansas
Recruiting Academic/Other
The study aims to develop a test for early detection of ovarian cancer using DNA from a growth involving the ovary found in a washing of the uterus (womb), and proteins found in the blood. The samples of the wash and the blood will be take…
Sponsor: Massachusetts General Hospital
NCT ID: NCT04794322
Sites in Arkansas: - University of Arkansas for Medical Sciences — Little Rock, Arkansas